Dr. Boyle is a co-founder of Abintus and serves as the President and Chief Executive Officer and is a Director of the company. He has over 15 years of operational experience building value at cell/gene therapy and oncology companies from start-up to commercial and has led or supported over $1 billion of transactions including licensing deals and private and public financings. Prior to founding Abintus, Dr. Boyle was Vice President, strategy and business development at Tocagen Inc. where he held broad responsibilities including strategy, commercial, medical affairs, contracts and business development. He also served on a board appointed committee resulting in a reverse merger transaction. Before joining Tocagen he was Director, corporate development at Spectrum Pharmaceuticals where he closed a sequence of licensing transactions that catalyzed a 10-fold increase in market value. Previously, Dr. Boyle was team leader for antiviral and oncology drug discovery at Biota (now Vaxart) and a medicinal chemist at SmithKline Beecham (now GSK). Dr. Boyle holds a Ph.D. in organic chemistry from Sheffield University, completed his post-doctorate research at The Scripps Research Institute, was a visiting scholar at The University of North Texas and received a Monbusho (AIST) fellowship to conduct gene editing and synthetic biology research in Tsukuba, Japan.